In 2008, the World Health Assembly called for the development of safe “also for production” and more affordable inactivated poliovirus vaccines (IPVs).1 The resolution led to the acceleration of several projects, including the development of IPV produced from Sabin poliovirus strains2 and evaluation of fractional-dose IPV.
Original Article: [Comment] Addressing the inactivated poliovirus vaccine shortage